Scribe Therapeutics priced an upsized CRISPR-focused IPO, raising about $129 million gross as it begins trading on Nasdaq under ticker SCTX. The company’s initial clinical strategy centers on in vivo gene editing that represses PCSK9 expression, with early-stage work for additional lipid and cardiometabolic targets planned to follow as proceeds move into trials.